INTERCEPT Safety Evaluation on Whole Blood

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

March 31, 2025

Conditions
Safety Issues
Interventions
DEVICE

Amustaline/GSH pathogen reduction technology

Whole blood treated with pathogen reduction technology

DEVICE

Standard of Care

Red Blood Cell Component or whole blood

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cerus Corporation

INDUSTRY

lead

Swiss Transfusion SRC

OTHER